

Clinical Policy: Insulin Delivery Systems (V-Go, Omnipod, InPen)

Reference Number: CP.PHAR.534

Effective Date: 06.01.21 Last Review Date: 05.25

Line of Business: Commercial, HIM, Medicaid

Coding Implications
Revision Log

See <u>Important Reminder</u> at the end of this policy for important regulatory and legal information.

Description

The following are insulin delivery systems* requiring prior authorization:

- V-Go® Wearable Insulin Delivery Device
- Omnipod DASH® Insulin Management System
- Omnipod® 5 Automated Insulin Delivery System
- InPen[™] System

FDA Approved Indication(s)

V-Go Wearable Insulin Delivery Device

- <u>Use</u>: Subcutaneous delivery of insulin to provide basal-prandial control.
 - The V-Go 20 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 20 Units of insulin in one 24-hour time period (0.83 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
 - The V-Go 30 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 30 Units of insulin in one 24-hour time period (1 .25 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
 - The V-Go 40 Disposable Insulin Delivery Device is indicated for continuous subcutaneous infusion of 40 Units of insulin in one 24-hour time period (1 .67 U/hr) and on-demand bolus dosing in 2-Unit increments (up to 36 Units per one 24-hour time period) in adult patients requiring insulin.
- Populations: Adult patients requiring insulin.*
 - *Patients who have to make regular adjustments or modifications to their basal rate during a 24-hour period, or whose amount of insulin used at meals requires adjustments of less than 2-Unit increments, should not use V-Go as it may result in hypoglycemia. V-Go has not been studied in patients who are pregnant or in patients diagnosed with gestational diabetes.
- <u>Components</u>: 1) V-Go device, 2) EZ Fill device
- <u>User guide and related resources</u>: https://www.go-vgo.com/educational-resources

Omnipod DASH Insulin Management System

• <u>Use</u>: Subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin.

^{*}If request is for an insulin delivery system that is also a continuous glucose monitor, additional approval criteria apply. Refer to the Continuous Glucose Monitor policy for the relevant line of business: CP.CPA.355 for commercial and CP.PMN.214 for Medicaid and health insurance marketplace.



- <u>Populations</u>: Appropriate for use in type 1 diabetes, insulin-requiring type 2 diabetes, gestational diabetes, and latent autoimmune diabetes. Omnipod DASH can be used by people of all ages. See https://www.myomnipod.com/healthcareproviders/about-omnipod/prescribe.
- <u>Components</u>: 1) Adhesive disposable pump (DASH Pod), 2) handheld DASH Personal Diabetes Manager (PDM) device, 3) compatible Contour[®] Next One blood glucose meter (BGM)
 - <u>Contour Next</u> test strips and control solution are used with the Contour Next One BGM for quantitative measurement of blood glucose (BG) in fresh capillary whole blood drawn from the fingertips or palm.*
- <u>Connectivity</u>: Wireless <u>Bluetooth communication</u> between the DASH Pod, DASH PDM, Contour Next BGM and, if desired, an iPhone (iPhone application does not include insulin management view only).**
- <u>User guide and related resources</u>: https://www.omnipod.com/current-podders/resources/omnipod-dash

Omnipod 5 Automated Insulin Delivery System

- <u>Use</u>: Subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin.
- <u>Populations</u>: The Omnipod 5 Alternate Controller Enabled (ACE) Pump is intended for the management of diabetes mellitus in persons requiring insulin. The SmartAdjust technology is intended for use in patients aged 2 years and older with type 1 diabetes and patients aged 18 years and older with type 2 diabetes. The SmartBolus Calculator is intended for use in patients aged 2 years and older with diabetes requiring rapid-acting U-100 insulin.
- <u>Components</u>: 1) Omnipod 5 ACE Pump (an adhesive disposable pump, or Pod), 2) Omnipod 5 App (on a provided Controller or installed on a compatible smartphone), 3) Dexcom G6[®], Dexcom G7[®], or FreeStyle Libre 2 Plus[®] continuous glucose monitoring (CGM) system (must be obtained separately)
- <u>Connectivity</u>: Wireless <u>Bluetooth communication</u> between the Pod; Dexcom G6, Dexcom G7, or FreeStyle Libre 2 Plus CGM; and provided Controller or compatible smartphone (https://omnipod.com/compatibility)
- <u>User guide and related resources</u>: https://www.omnipod.com/sites/default/files/Omnipod-5 User-guide.pdf

InPen System

- Use: Self-injection of a desired dose of insulin.
- Populations: Patients 7 years of age and older with diabetes.
- Components: 1) InPen smart insulin pen (reusable pen injector), 2) InPen App
 - O The pen injector is compatible with Lilly Humalog[®] U-100 3.0 mL cartridges, Novo Nordisk Novolog[®] U-100 3.0 mL cartridges, and Novo Nordisk Fiasp[®] U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included).

^{*}The Contour Next One BGM is intended for single-patient use and should not be shared. The BGM should not be used for the diagnosis of or screening for diabetes or for neonatal use.

^{**}Data may be uploaded to Insulet provided Glooko® software allowing sharing with caregivers and providers and access from anywhere (Cloud capability data sharing available). See https://support.glooko.com/hc/en-us for more information.



- <u>Connectivity</u>: Wireless <u>Bluetooth communication</u> between the InPen and a smart mobile device (iOS 10 or later; Android 6 or later) via the InPen App
 - o The system may also be connected to a continuous glucose monitor (Medtronic, Dexcom, or Abbot) and Apple Health.
- <u>User guide and related resources</u>: https://www.companionmedical.com/guides/inpen-user-guide.pdf

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that V-Go, Omnipod DASH, Omnipod 5, and InPen are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

- A. Diabetes Mellitus (must meet all):
 - 1. Diagnosis of diabetes mellitus;
 - 2. Prescribed by or in consultation with an endocrinologist;
 - 3. If request is for V-Go, age \geq 18 years;
 - 4. If request is for InPen, age ≥ 7 years;
 - 5. If request is for Omnipod 5, age \geq 2 years;
 - 6. Member has utilized one of the following insulin administration methods for at least the last 6 months (a or b):*
 - *For Illinois HIM requests, the step therapy requirements below do not apply as of 1/1/2026 per IL HB 5395
 - a. Continuous insulin delivery system (see Appendix B for examples);
 - b. Multiple daily insulin injections (meets i and ii):
 - i. Administration of at least 3 daily injections of a basal and bolus insulin regimen (see Appendix B for examples of basal [intermediate- or long-acting] and bolus [short- or rapid-acting] insulin);
 - ii. History of suboptimal blood sugar control despite appropriate management examples of suboptimal control include, but are not limited to, any of the following (1-6):
 - 1) Repeated hypoglycemic events (BG < 70 mg/dL);
 - 2) Repeated episodes of diabetic ketoacidosis;
 - 3) Wide blood sugar excursions;
 - 4) Hypoglycemia unawareness;
 - 5) Glycosylated hemoglobin level (HbA1c) \geq 7.0;
 - 6) "Dawn phenomenon" with fasting blood sugars repeatedly > 200 mg/dL;
 - 7. Member has monitored $BG \ge 4$ times a day for at least the last 6 months;
 - 8. If request is for InPen, medical justification supports necessity of the digital component (i.e., rationale why insulin dose/usage cannot be calculated/tracked manually for example, the member has an intellectual disability and no caregivers are available to assist with insulin dose calculation);
 - 9. Request meets one of the following (a, b, or c):
 - a. V-Go: Number of devices does not exceed 30 per month;*



*For requests exceeding 30 devices per month, a clinical rationale with documentation to support the higher quantity is required.

- b. Omnipod DASH/Omnipod 5: Both of the following (i and ii):
 - i. Number of Pods does not exceed 10 per month;*

 *For requests exceeding 10 Pods per month, a clinical rationale with documentation to support the higher quantity is required.
 - ii. Number of devices does not exceed 1 per 4 years;
- c. InPen: Request does not exceed 1 system per year.

Approval duration:

Medicaid/HIM: V-Go (6 months), Omnipod DASH/Omnipod 5 (Pods – 6 months, device – 30 days), InPen (12 months – one device per year)

Commercial: V-Go (6 months or to the member's renewal date, whichever is longer), Omnipod DASH/Omnipod 5 (Pods – 6 months or to the member's renewal date, whichever is longer, device – 30 days), InPen (6 months or to the member's renewal date, whichever is longer – one device per year)

B. Other diagnoses/indications (must meet 1 or 2):

- 1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business:
 CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
- 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Diabetes Mellitus (must meet all):

- 1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
- 2. Member is responding positively to therapy;
- 3. Member is adherent to provider follow-up visits and training;
- 4. Request meets one of the following (a, b, or c):
 - a. V-Go: Number of devices does not exceed 30 per month;*



*For requests exceeding 30 devices per month, a clinical rationale with documentation to support the higher quantity is required.

- b. Omnipod DASH/Omnipod 5: Both of the following (i and ii):
 - i. Number of Pods does not exceed 10 per month;*

 *For requests exceeding 10 Pods per month, a clinical rationale with documentation to support the higher quantity is required.
 - ii. Number of devices does not exceed 1 device per 4 years;
- c. InPen: Request does not exceed 1 system per year.

Approval duration:

Medicaid/HIM: V-Go (12 months), Omnipod DASH/Omnipod 5 (Pods – 12 months, device – 30 days), InPen (12 months – one device per year)

Commercial: V-Go (6 months or to the member's renewal date, whichever is longer), Omnipod DASH/Omnipod 5 (Pods – 6 months or to the member's renewal date, whichever is longer, device – 30 days), InPen (6 months or to the member's renewal date, whichever is longer – one device per year)

B. Other diagnoses/indications (must meet 1 or 2):

- 1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business:
 CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
- 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key ACE: alternate controller enabled

BG: blood glucose

BGM: blood glucose meter

CGM: continuous glucose monitoring

CSII: continuous subcutaneous insulin infusion

FDA: Food and Drug Administration GLP-1: glucagon-like peptide-1

MDI: multiple daily doses of insulin



PDM: Personal Diabetes Manager T1DM: type 1 diabetes mellitus Pod: tubeless insulin pump T2DM: type 2 diabetes mellitus

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business

and may require prior authorization.

Drug Name	Dosing	Dose Limit/ Maximum Dose
CONTINUOUS INCUI IN DELIVEDY SYSTEMS	Regimen	
CONTINUOUS INSULIN DELIVERY SYSTEMS	Varies	Varies
Insulin pumps (with tubing [automated options available])		
• MiniMed TM System (530G, 630G, 670G)		
MiniMed [™] Paradigm Revel [™] The Mark Paradigm Reve		
• t:slim [™] X2 Insulin Pump		
Insulin pumps (without tubing)		
Omnipod DASH Insulin Management System		
Omnipod 5 Automated Insulin Delivery System		
Insulin patches		
• V-Go 20, 30, 40 Wearable Insulin Delivery Device		
(disposable)	** '	** •
INSULIN	Varies	Varies
Human Insulin		
Short-acting:		
• Regular insulin (HumuLIN® R U-500, HumuLIN® R U-		
500 KwikPen [®] , HumuLIN [®] R [OTC], NovoLIN [®] R		
ReliOn [OTC], NovoLIN® R [OTC])		
Intermediate-acting:		
• Insulin NPH (HumuLIN® N KwikPen® [OTC],		
HumuLIN® N [OTC], NovoLIN® N ReliOn [OTC],		
NovoLIN® N [OTC])		
Intermediate-acting and short-acting combinations:		
• Insulin NPH and regular insulin (HumuLIN® 70/30,		
HumuLIN® 70/30 KwikPen®, NovoLIN® 70/30)		
Insulin Analogs		
Rapid-acting		
• Insulin glulisine (Apidra, Apidra SoloStar®)		
• Insulin lispro (Admelog, Admelog SoloStar®,		
HumaLOG [®] , HumaLOG Junior KwikPen [®] , HumaLOG		
KwikPen [®] , Lyumjev [®])		
• Insulin aspart (Fiasp [®] , Fiasp FlexTouch [®] , NovoLOG [®] ,		
NovoLOG FlexPen®, NovoLOG PenFill®)		
Intermediate-acting and short-acting combinations:		
• Insulin aspart protamine and insulin aspart (NovoLOG		
Mix [®] 70/30, NovoLOG Mix 70/30 FlexPen [®])		



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
 Insulin lispro protamine and insulin lispro (HumaLOG Mix®, HumaLOG Mix® 50/50, HumaLOG Mix 50/50 KwikPen®, HumaLOG Mix® 75/25, HumaLOG Mix 75/25 KwikPen®) Long-acting Insulin glargine (Basaglar KwikPen®, Lantus®, Lantus SoloStar®, Toujeo Max SoloStar®, Toujeo SoloStar®) Insulin detemir (Levemir®, Levemir FlexTouch®) Insulin degludec (Tresiba®, Tresiba FlexTouch®) 		
 ANTIDIABETIC AGENTS Biguanide: metformin Sulfonylureas: glipizide, glimepiride, glyburide Thiazolidinedione: pioglitazone GLP-1 receptor agonists: dulaglutide (Trulicity®), exenatide ER (Bydureon®, Bydureon BCise®), exenatide IR (Byetta®), liraglutide (Victoza®), liraglutide/insulin degludec (Xultophy®), lixisenatide/insulin glargine (Soliqua®), semaglutide (Ozempic®, Rybelsus®), tirzepatide (Mounjaro™) SGLT2 inhibitors: bexagliflozin (Brenzavvy™), canagliflozin (Invokana®), canagliflozin/metformin (Invokamet®, Invokamet® XR), dapagliflozin (Farxiga®), dapagliflozin/metformin (Xigduo® XR), dapagliflozin/saxagliptin (Qtern®), empagliflozin (Jardiance®), empagliflozin/linagliptin (Glyxambi®), empagliflozin/linagliptin/metformin (Trijardy™ XR), empagliflozin/metformin (Synjardy®, Synjardy® XR), ertugliflozin/sitagliptin (Steglujan™), sotagliflozin (Inpefa™) DPP-4 inhibitors: alogliptin (Nesina®), alogliptin/metformin (Jentadueto®, Jentadueto® XR), saxagliptin/metformin (Jentadueto®, Jentadueto® XR), saxagliptin (Onglyza®), saxagliptin/metformin (Kombiglyze® XR), sitagliptin (Januvia®, Zituvio™), sitagliptin/metformin (Janumet®, 	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

• Contraindication(s):

Omnipod DASH and Omnipod 5 are not recommended for people who are:

• Unable to monitor glucose as recommended by their healthcare provider (at least 4 blood glucose tests per day for Omnipod DASH)



- o Unable to maintain contact with their healthcare provider
- o Unable to use the System according to instructions

Omnipod 5 is additionally not recommended for people who:

- o Are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia
- o Do not have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders

InPen is not intended for anyone unable or unwilling to:

- o Test blood glucose levels as recommended by a healthcare provider
- o Maintain sufficient diabetes self-care skills
- Visit a healthcare provider regularly
- Boxed warning(s): none reported

V. Dosage and Administration

	Dosage and Administration			
Dosing Regimen	Maximum			
	Dose			
 V-Go is designed for 24-hour wear and requires one insulin type – U-100 fast-acting insulin. Humalog (insulin lispro, rDNA origin) and NovoLog (insulin aspart, rDNA origin) have been tested and found to be safe for use in V-Go. Stability and storage: Humalog has been tested in V-Go and has been demonstrated to be stable for up to 24 hours refrigerated or at room temperature followed by 24 hours wear. NovoLog has been demonstrated to be stable for up to 5 days refrigerated or 3 days at room temperature followed by 24 hours wear. The EZ Fill has been demonstrated to be acceptable for filling Humalog and NovoLog for up to 30 days. Description: V-Go is a mechanical (no electronics), self-contained, sterile, patient fillable, single-use disposable insulin infusion device with an integrated stainless steel subcutaneous needle. It is designed for the subcutaneous infusion of insulin. After filling V-Go with insulin using the EZ Fill, V-Go is secured to the patient's skin over the infusion site with an adhesive backed foam pad. Once activated, V-Go delivers a continuous infusion of insulin at a fixed rate. V-Go also allows the user to initiate bolus injections to supplement their daily basal insulin requirements. A window in the 				
	 insulin type – U-100 fast-acting insulin. Humalog (insulin lispro, rDNA origin) and NovoLog (insulin aspart, rDNA origin) have been tested and found to be safe for use in V-Go. Stability and storage: Humalog has been tested in V-Go and has been demonstrated to be stable for up to 24 hours refrigerated or at room temperature followed by 24 hours wear. NovoLog has been demonstrated to be stable for up to 5 days refrigerated or 3 days at room temperature followed by 24 hours wear. The EZ Fill has been demonstrated to be acceptable for filling Humalog and NovoLog for up to 30 days. Description: V-Go is a mechanical (no electronics), self-contained, sterile, patient fillable, single-use disposable insulin infusion device with an integrated stainless steel subcutaneous needle. It is designed for the subcutaneous infusion of insulin. After filling V-Go with insulin using the EZ Fill, V-Go is secured to the patient's skin over the infusion site with an adhesive backed foam pad. Once activated, V-Go delivers a continuous infusion of insulin at a fixed rate. V-Go also allows the user 			



Drug Name	Dosing Regimen	Maximum Dose
Omnipod DASH Insulin Management System See User Guide for more information: https://www.omnipod.co m/current- podders/resources/omni pod-dash	 Initial Omnipod DASH System use Provider recommends initial program settings and meets with patient and Omnipod System Trainer to program the PDM device and first Pod. Filling the Pod The Pod is filled with insulin FDA approved for insulin pumps (i.e., the following rapid-acting U100 insulin analogs: insulin glulisine (Apidra), insulin lispro (Admelog, HumaLOG, Lyumjev), insulin aspart (Fiasp, NovoLOG)). Pod capacity accommodates 85 to 200 units of insulin depending on patient need (for initial programming, each Pod must be filled with at least 85 units of insulin). Pod priming The PDM device and Pod are placed next to each other so that the PDM may prime the Pod. Pod placement For site selection, see User Guides. Pod activation The Pod features an insulin-providing cannula that inserts automatically with the press of an "activate" button on the PDM device. Pod replacement The Pod may remain on the skin from 1 to 3 days after which a new Pod should be filled, primed, applied, and activated. 	200 units per day (1 Pod)
InPen System See User Guide for more information: https://www.companion medical.com/guides/inpe n-user-guide.pdf	 Determining the dose The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments. For doses greater than 30 units the dose must be split into multiple doses. The InPen dose calculator is a component of the InPen App. It can calculate an insulin dose or carbohydrate intake based on user entered data. For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin 	Not applicable



Drug Name	Dosing Regimen	Maximum Dose
	sensitivity parameters to be programmed into the software prior to use. For an insulin dose based on fixed/variable meal sizes, a healthcare professional must provide patient-specific fixed doses/meal sizes to be programmed into the software prior to use. Injecting the dose Insert the insulin cartridge into the cartridge holder of the InPen. Attach the needle and prime the pen. The pen must be primed before every injection. Select the dose by turning the dose knob. Insert the needle into the upper arms, stomach, or thighs. Place thumb on the injection button, then slowly and firmly push the button until it stops moving. Continue to hold the button for 8 seconds and then remove the needle from the skin. Check to make sure there is a 0 in the dose window to confirm the complete dose has been received. Remove and discard the needle into a sharps container.	
	 Container. Handling and storage When an insulin cartridge is installed in the InPen, store the InPen at room temperature. Refer to the insulin manufacturer or literature that came with the insulin for information on how to store the cartridges and how long to keep them. Remove the needle after every use. Do not store the InPen with the needle attached. Do not store the InPen in a refrigerator. Cleaning the device The InPen should be cleaned whenever it is 	
	visibly dirty. Clean the InPen as needed only with a soft cloth moistened with water, being careful not to get water inside. Never submerge the InPen. If insulin gets on the InPen, clean it off right away. • Replacements • The InPen has a 1-year life. It contains a lithium battery which is not replaceable.	



Drug Name	Dosing Regimen	Maximum
Omnipod 5 Automated Insulin Delivery System	o A low battery icon will appear on the InPen App when the InPen is reaching the end of its life and needs to be replaced. • There is no tubing with the Pod allowing placement almost anywhere an injection would be given. The Pod may be worn for up to 3 days and can be filled with up to 200 units of U-100 rapid-acting insulin (minimum 85 units). • The Pod, SmartAdjust technology, and SmartBolus Calculator are compatible with the following U-100 insulins: NovoLOG, HumaLOG, and AdmeLOG. • The Omnipod 5 App allows the patient to select a basal profile, target glucose and bolus settings, activate and deactivate the Pod, connect with the Dexcom G6/G7 or FreeStyle Libre 2 Plus CGM, and select insulin delivery mode • The Omnipod 5 System communicates with the Dexcom G6/G7 and FreeStyle Libre 2 Plus CGM Systems. CGM values and trends from the Dexcom G6/G7 and FreeStyle Libre 2 Plus are used for automated insulin delivery in Automated Mode, as well as bolus calculations in both Automated and Manual Mode. The CGM sensor must be started in the CGM app in order to use CGM values and trends in the Omnipod 5 System. • There are 2 modes of operation: Automated and Manual. ○ In Automated mode, SmartAdjust technology adjusts insulin every 5 minutes to bring the glucose value to the customized glucose target, or Target Glucose. The adjustment is based on a prediction of where your glucose will be 60 minutes in the future and considers your CGM value and trend, adaptive basal rate, and insulin that is still working in your body.	Maximum Dose 200 units per day (1 Pod)
	 In Manual mode, the Omnipod 5 System delivers insulin based on user-defined Basal Programs. During Manual Mode, there is no automated adjustment of insulin delivery. 	



VI. Product Availability

Drug Name	Availability
V-Go 20, 30, 40	V-Go is available as a 30-day supply in 3 options – V-Go
	20, V-Go 30, and V-Go 40.
Omnipod DASH Insulin	Omnipod Pack 5 (packs of 5 Pods)
Management System	Starter Kit (PDM DASH device plus a separate but
All Omnipod DASH	compatible Contour® Next One BGM)*
components (Pod, PDM,	*The compatible Contour Next One BGM must be used with Ascensia
compatible BGM) have	Contour® Next test strips and control solution; however, patients may
Bluetooth connectivity that is compatible with the iPhone.	choose to use other blood glucose testing methods with manual entry
	into the PDM device.
InPen System	• InPen smart insulin pen for use with Humalog: blue, grey,
	pink
	• InPen smart insulin pen for use with Novolog/Fiasp: blue,
	grey, pink
Omnipod 5 Automated	Omnipod 5 Intro Kit (Omnipod 5 Controller and Pods plus
Insulin Delivery System	a separate but compatible CGM [Dexcom G6, Dexcom G7,
	or FreeStyle Libre 2 Plus])
	Omnipod 5 Refill 5 Pack Pods

VII. References

V-Go

FDA 510(k) device summary

- 1. V-Go Insulin Delivery System 510(k) summary, No. K103825. Shrewsbury, MA: Valeritas, Inc.; February 2011. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103825.pdf. Accessed February 3, 2025.
- User guides
- 2. Instructions for Patient Use. P/N 2614-00 Rev. D 07/2023. Available at: https://www.govgo.com/educational-resources. Accessed January 8, 2025.

Clinical trials and reviews

- 3. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Effectiveness of V-Go for patients with type 2 diabetes in a real-world setting: A prospective observational study. Drugs Real World Outcomes. 2020 Mar;7(1):31-40. 5.
- 4. Sutton D, Higdon C, Nikkel C, Hilsinger K. Clinical benefits over time associated with use of V-Go Wearable Insulin Delivery Device in adult patients with diabetes: a retrospective analysis. Advances in Therapy 2018 May; 35(5): 631-43.
- 5. Lajara R, Fetchick DA, Morris DA, Nikkel C. Use of V-Go insulin delivery device with suboptimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6(4):531-545.
- 6. Lajara R, Davidson JA, Nikkel C, Morris TL. Clinical and cost effectiveness of insulin delivery with V-Go disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. Endocrine Practice 2016 June;22(6):726-735.



Omnipod DASH, Omnipod 5

FDA 510(k) device summary

- 7. Omnipod Insulin Management System and Omnipod DASH Insulin Management System 510(k) summary, No. K192659. Acton, MA: Insulet Corporation; October 2021. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192659.pdf. Accessed February 3, 2025.
- 8. Omnipod 5 ACE Pump (Pod) 510(k) summary, No. K203768. Acton, MA: Insulet Corporation; January 2022. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203768.pdf. Accessed February 3, 2025.
- 9. Omnipod 5 SmartBolus Calculator 510(k) summary, No. K203772. Acton, MA: Insulet Corporation; January 2022. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203772.pdf. Accessed February 3, 2025.
- 10. SmartAdjust Technology 510(k) summary, No. K203774. Acton, MA: Insulet Corporation; January 2022. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203774.pdf. Accessed February 3, 2025.

User guides

- 11. Omnipod DASH Insulin Management System User Guide. Available at https://www.omnipod.com/current-podders/resources/omnipod-dash. Last updated April 2021. Accessed January 8, 2025.
- 12. Omnipod 5 Automated Insulin Delivery System User Guide, Rev 04. Available at https://www.omnipod.com/sites/default/files/Omnipod-5_User-guide.pdf. Last updated April 2025. Accessed August 27, 2025.

Clinical trials and reviews

- 13. Layne JE, Parkin CG, Zisser H. Efficacy of the Omnipod Insulin Management System on glycemic control in patients with type 1 diabetes previously treated with multiple daily injections or continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2016;10(5):1130-1135.
- 14. Layne JE, Parkin CG, Zisser H, et al. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. J Diabetes Sci Technol. 2017;11(1):178-179.
- 15. Ly TT, Layne JE, Huyett LM, et al. Novel Bluetooth-enabled tubeless insulin pump: innovating pump therapy for patients in the digital age. J Diabetes Sci Technol. 2019;13(1):20-26.

InPen

FDA 510(k) device summary

16. InPen System 510(k) summary, No. K160629. San Diego, CA: Companion Medical, Inc.; July 2016. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160629.pdf. Accessed February 3, 2025.

User guides

17. Instructions for Use. Available at https://www.companionmedical.com/guides/inpen-user-guide.pdf. Last updated June 2023. Accessed January 8, 2025.

Reviews

18. Gildon BW. InPen smart insulin pen system: product review and user experience. Diabetes Spectrum. 2018; 31(4): 354-358.



Insulin Products

19. Lexicomp Online, Insulin Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2024. Accessed February 3, 2025.

Continuous Insulin Delivery Systems

- 20. Section 7, diabetes technology: Standards of medical care in diabetes 2025. American Diabetes Association. Diabetes Care. 2025; 48 (Supplement 1): S146-S166. https://doi.org/10.2337/dc25-S007.
- 21. Section 9, pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2025. American Diabetes Association. Diabetes Care. 2025; 48 (Supplement 1): S181-S206. https://doi.org/10.2337/dc25-S009.
- 22. Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocrine Practice; March 2018: 24(3): 302-308.
- 23. Peters AL, Ahmann AJ, Hirsch IB, et al. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. J Endocr Soc; October 5 2018; 2(11): 1214-1225.
- 24. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocrine Practice. 2021; 27: 505-537.

Diabetes and Pregnancy

25. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. November 2013; 98(11): 4227-49.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS	Description*
Codes	
A9274	External ambulatory insulin delivery system, disposable, each, includes all
	supplies and accessories (Suggest NDC level or Invoice pricing) (Pod)
E0784	External ambulatory infusion pump, insulin (PDM device)
A4211	Supplies for self-administered injection

*A9274 and E0784: Omnipod System (note: these codes do not apply to Omnipod DASH or Omnipod 5, which are available only through pharmacy distribution); A9274: V-Go; A4211: not specific but can be applied to InPen. Note: S5561 (Insulin delivery device, reusable pen) does NOT apply to InPen.

NDCs	Description
62088000031	InPen Humalog, blue
62088000032	InPen Humalog, grey
62088000033	InPen Humalog, pink
62088000034	InPen Novolog/Fiasp, blue
62088000035	InPen Novolog/Fiasp, grey
62088000036	InPen Novolog/Fiasp, pink



NDCs	Description
08508200005	Omnipod DASH 5 Pack Pods
08508200000	Omnipod DASH PDM Kit
08508200032	Omnipod DASH Intro Kit
08508300021	Omnipod 5 DexG7G6 Pods (Gen 5)
08508300001	Omnipod 5 DexG7G6 Intro (Gen 5)
08508300088	Omnipod 5 Intro (G6/Libre 2 Plus)
08508300042	Omnipod 5 Pods (G6/Libre 2 Plus)

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created: adapted from CP.PHAR.505 Continuous Insulin Delivery Systems (now retired); added InPen; references to HIM.PHAR.21 revised to HIM.PA.154.	04.06.21	05.21
2Q 2022 annual review: no significant changes; added Omnipod 5; references reviewed and updated.	02.03.22	05.22
Added footnote referring reviewers to the Continuous Glucose Monitors policies for requests for insulin delivery systems that also functions as continuous glucose monitors. Template changes applied to other diagnoses/indications and continued therapy section.	08.18.22	
For Omnipod 5, revised minimum age requirement from 6 years to 2 years per updated user guide.	10.17.22	
2Q 2023 annual review: no significant changes; for V-Go, revised minimum age requirement from 21 years to 18 years per user guide; references reviewed and updated.	01.24.23	05.23
Per SDC and line of business owner, modified from HIM-Medical Benefit to HIM.	06.13.23	
Added Omnipod GO and corresponding criteria; removed Omnipod as it will no longer be available in the US after 12/31/23 per the manufacturer.	11.14.23	02.24
2Q 2024 annual review: no significant changes; references reviewed and updated. For Omnipod 5, updated the following sections to reflect newly approved compatibility with Dexcom G7: FDA Approved Indication(s), Dosing and Administration, and NDCs.	04.08.24	05.24
For Omnipod DASH and Omnipod 5, moved device limit (1 per 4 years) from approval duration to criteria and revised approval duration to 30 days due to operational limitations for benefit programming. Added NDC for Omnipod DASH PDM Kit per request.	07.09.24	
For Omnipod 5, updated the FDA Approved Indication section to reflect newly approved use of the SmartAdjust technology in adults with type 2 diabetes.	09.04.24	



Reviews, Revisions, and Approvals	Date	P&T
		Approval Date
Added Appendix D with description of a comprehensive diabetes	11.27.24	
management program.		
Per SDC, removed requirement for participation in a	01.07.25	02.25
comprehensive diabetes management program.		
2Q 2025 annual review: no significant changes; references	02.03.25	05.25
reviewed and updated.		
Added step therapy bypass for IL HIM per IL HB 5395.	06.25.25	
Per manufacturer, removed Omnipod GO criteria as this product	08.27.25	
was never launched in the marketplace; for Omnipod 5, updated the		
following sections to reflect newly approved compatibility with		
FreeStyle Libre 2 Plus: FDA Approved Indication(s), Dosing and		
Administration, and NDCs.		

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.



This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.